Yoshida et al. 1 recently described recurrent somatic mutations that involved different components of the RNA splicing machinery and other spliceosome-related genes in 209 of 582 patients with myeloid neoplasms: 228 with myelodysplastic syndromes (MDS) with (n ¼ 73) or without (n ¼ 155) ring sideroblasts (RS), 88 with chronic myelomonocytic leukemia (CMML), 151 with primary acute myeloid leukemia (AML), 62 with AML that is therapy-related or displayed MDS-like features (t-AML/MDS) and 53 with myeloproliferative neoplasms (MPN). Mutational frequencies were B85% in MDS-RS, 44% in MDS without RS, 55% in CMML, 26% in t-AML/MDS, 7% in primary AML and 9% in MPN. In MDS-RS, the most frequent (75.3%) spliceosome mutations involved splicing factor 3B subunit 1 (SF3B1) with mutational frequencies of 83% in refractory anemia with RS (RARS) and 76% in refractory cytopenia with multilineage dysplasia-RS. SF3B1 mutations were less frequent in MDS without RS (6.5%) or other myeloid neoplasms (o5%); none of the MPN cases displayed SF3B1 mutations. Mutations involving the serine/arginine-rich (SR) protein, SRSF2, were more frequent in CMML (28.4%), MDS without RS (11.6%) or t-AML/MDS (6.5%). The authors also described other spliceosome component mutations that involved genes encoding for U2 auxiliary factor small nuclear ribonucleoprotein (snRNP) complexes including U2AF35 and U2AF65, zinc finger, RNA-binding motif and serine/arginine-rich (SR) protein 2 (ZRSR2), SF3A1, SF1 and PRP40 pre-mRNA processing factor 40 homolog B (PRPF40B). 1 These mutations were mutually exclusive and their common functional consequence is believed to involve global abnormalities in RNA splicing, resulting in reduced cell proliferation and increased apoptosis. 1 SF3B1 (located on chromosome 2q33.1) mutations in MDS-RS have also been reported by Papaemmanuil et al. 2 and Visconte et al. 3 At the time of this writing, details regarding the former study 2 were not available, whereas in the latter study 3 heterozygous SF3B1 mutations were reported in 9 (64%) of 14 patients with RARS, 13 (72%) of 18 patients with RARS and marked thrombocytosis (RARS-T), and none of 24 patients with MDS/MPN without RS. 3 The most common SF3B1 mutation reported by Visconte et al. 3 was SF3B1K700E (64%); other mutations described by these authors involved K666 (n ¼ 3), R625 (n ¼ 2), E622 (n ¼ 1), H662 (n ¼ 1) and del699-700QK (n ¼ 1). In the aforementioned study by Yoshida et al.,
1 SF3B1 mutations also involved K700, K666, H662 and E622. Visconte et al. 3 demonstrated that JAK2, MPL, LNK or DNMT3A mutations can co-occur with SF3B1 mutations and suggested an association between SF3B1 mutations and thrombosis. 3 The objective of the current study was to define the prevalence of SF3B1 mutations in chronic-phase primary myelofibrosis (PMF) and investigate its prognostic relevance and phenotypic correlates. We were particularly interested in the presence or absence of bone marrow RS in SF3B1-mutated cases and whether or not the reported association with thrombosis can be confirmed.
The current study was approved by the Mayo Clinic institutional review board. Study patients were recruited from Mayo Clinic databases of patients with PMF in whom complete clinical and laboratory information was available and in whom stored DNA was available for SF3B1 mutation screening. In SF3B1-mutated patients, bone marrow pathology slides, including iron stains, were centrally re-reviewed in order to confirm morphological diagnosis and to quantify bone marrow RS percentage. Detailed analysis of clinical parameters and cytogenetic findings was performed to risk stratify patients according to the Dynamic International Prognostic Scoring System (DIPSS)-plus. 4 All patients were also screened for JAK2, MPL and IDH mutations, using previously described methods.
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SF3B1-coding exon sequencing was performed using bone marrow-or granulocyte-derived DNA extract (Qiagen, Valencia, CA, USA). Individual mutations were examined and excluded for occurrence in normal genetic variation by interrogation of the NCBI single-nucleotide polymorphism (dbSNP) database. All products were confirmed by 1% agarose gel, purified using QIAquick Spin Kit (Qiagen, Santa Clarita, CA, USA) and submitted for sequencing using two ABI PRISM 3730xl DNA Analyzers (Applied Biosystems Inc., Foster City, CA, USA) (96-capillary). In order to confirm previous observations and to determine regions of frequent mutation occurrence, we first sequenced all SF3B1-coding exons in 10 RARS cases and identified six patients with SF3B1 mutations that clustered in exons 14 and 15 (data not shown). Accordingly, only exons 13 --15 were sequenced in our study patients with PMF; 50 --100 ng DNA was added to a 50 ml final volume mixture of: 5 ml 10 Â PCR Buffer (Roche Diagnostics, Indianapolis, IN, USA), 1.5 ml of dNTP (10 mM of each), 0.5 ml of Taq Polymerase (Roche Diagnostics), and 2 ml each of a 10 mM stock of forward (SH3B1 FP 5 0 -TAGAGTGGAAGGCCGAGAGA-3 0 ) and reverse (SH3B1 RP 5 0 -TTCAAGAAAGCAGCCAAACC-3 0 ) primers, supplemented with PCR grade water. Parameters for this PCR amplification included an initial denaturation step of 95 1C for 2 min, followed by 35 cycles of an initial melt at 95 1C for 15 s, annealing at 60 1C for 45 s, extension at 72 1C for 1:10 min and a final extension step of 72 1C for 3 min. The products were purified with QIAquick Spin Kit (Qiagen). Sequencing was performed bidirectionally. Standard statistical methods were used for parameter comparison and survival curves were prepared by the Kaplan --Meier method and compared by the log-rank test. P-values o0.05 were considered significant. The Stat View (SAS Institute, Cary, NC, USA) statistical package was used for all analyses.
A total of 155 patients were studied and their clinical and laboratory characteristics are listed in Table 1 . Median age was 63 years and 61% were males. DIPSS-plus risk distributions were 15% low, 17% intermediate-1, 35% intermediate-2 and 34% high risk. Hemoglobin level was below 10 g/dl in 43% of the patients and 30% were red blood cell transfusion dependent at time of referral. All study patients were fully annotated for JAK2, MPL and IDH mutations, which were detected in 57%, 9% and 5% of the patients, respectively. Cytogenetic studies were abnormal in 39% of the patients including 29% with favorable and 10% with unfavorable karyotype. SF3B1 mutations were detected in 10 (6.5%) of the 155 study patients with PMF: 4 (40%) K700E, 4 (40%) K666T/N/M, 1 (10%) H662D and 1 (10%) N626S. In all, 6 (60%) of the 10 SF3B1-mutated patients also carried JAK2V617F and 1 (10%) carried MPLW515L; none were positive for IDH mutations. Extensive clinical and laboratory correlative studies revealed no associations between the presence of SF3B1 mutations and clinical features, karyotype, JAK2 or MPL mutations, with exception of marked splenomegaly that occurred more often in SF3B1-mutated cases (Table 1 ). In particular, in contrast to the report by Visconte et al., 3 we found no association between SF3B1 mutations and thrombosis (Table 1) . Furthermore, SF3B1 mutations did not influence survival (Figure 1 ). Bone marrow was evaluable for iron stains in 6 of the 10 SF3B1-mutated cases and revealed the presence of RS in all 6 (100%) cases with a median RS percentage of 58% (range 18 --72%). It is to be recalled that the one SF3B1-mutated post-polycythemia vera myelofibrosis case reported by Visconte et al.
3 also displayed bone marrow RS.
The current study demonstrates the infrequent occurrence of SF3B1 mutations in PMF, their lack of prognostic relevance and their apparently invariable association with bone marrow RS. The clinical, cytogenetic and molecular similarity between SF3B1-mutated and SF3B1-unmutated PMF suggests that the former is not a distinct clinicopathological entity but the result of a secondary mutation that promotes the formation of RS. Accordingly, it is possible that the percentage of bone marrow RS reflects the clone size that is affected by SF3B1 mutation. This particular observation is consistent with the aforementioned close association between MDS-RS and SF3B1 mutations, and is strongly suggestive of a causal relationship between SF3B1 mutations and the RS phenotype. RS are also found in hereditary sideroblastic anemias, including those with germline ABCB7 (ATP-binding cassette, sub-family B, member 7) mutations. ABCB7 is a mitochondrial iron transporter molecule and the downregulation of ABCB7 has been reported in RARS. 8 Therefore, it is conceivable that SF3B1 mutations induce RS formation by downregulating ABCB7 expression. According to Yoshida et al.,
1 SF3B1 is only one of many genes in the RNA spliceosome pathway that can be affected by functionally relevant mutations in myeloid neoplasms. Therefore, it is reasonable to hypothesize that other spliceosome component mutations account for the presence of RS in SF3B1-unmutated myeloid neoplasms. At the same time, the functional consequence of such mutations probably extends beyond induction of RS.
